english.prescrire.org > Spotlight > 100 most recent > Sample Free Download article (titre court pour FB et Twitter)

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

In the December issue of Prescrire International: pertuzumab (Perjeta°) after surgery for some breast cancers at high risk of recurrence

FREE DOWNLOAD Pertuzumab (Perjeta°) is a monoclonal antibody which has been authorised for use after surgery for some breast cancers. How do Prescrire's editors rate the drug's harm-benefit balance in this situation, in light of the most recent evidence?
Full text available for free download.

Summary

  • Pertuzumab (Perjeta°, Roche) is a monoclonal antibody with anti-HER2 activity. In the neoadjuvant setting, i.e. before surgery, it has an unfavourable harm-benefit balance.
     
  • Pertuzumab has also  been authorised for use after surgery, in addition to trastuzumab and chemotherapy, in women with non-metastatic breast cancer overexpressing HER2 protein and at high risk of recurrence.
     
  •  NOT ACCEPTABLE  Pertuzumab compared to placebo: survival rate the same and risk of invasive disease almost unchanged, but a higher risk of adverse effects, in particular heart failure.

Full text available for free download.

 ©Prescrire 1 December 2019

"Pertuzumab (Perjeta°) after surgery for some breast cancers at high risk of recurrence" Prescrire Int 2019; 28 (210): 292. (Pdf, free).

Share Share on Facebook Share on Twitter
Share
Partager sur Facebook Partager sur Twitter

 
Download the full review
Pdf, free
 
Prescrire's rating:
Prescrire's rating
  NOT ACCEPTABLE